EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with in vivo activity by N-(4-((3-bromophenyl)amino)-6-quinazolinyl)-2-butynamide (CL-387,785)



Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with in vivo activity by N-(4-((3-bromophenyl)amino)-6-quinazolinyl)-2-butynamide (CL-387,785)



Biochemical Pharmacology 57(8): 917-925



It has been shown previously that 4-anilino quinazolines compete with the ability of ATP to bind the epidermal growth factor receptor (EGF-R), inhibit EGF-stimulated autophosphorylation of tyrosine residues in EGF-R, and block EGF-mediated growth.

(PDF emailed within 1 workday: $29.90)

Accession: 010885738

Download citation: RISBibTeXText



Related references

Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with in vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387,785). Biochemical Pharmacology 57(8): 917-925, 1999

Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with in vivo activity by N- amino-6-quinazolinyl-2-butynamide. Biochemical Pharmacology 57(8): 917-925, April 15, 1999

Tyrosine kinase inhibitors. 13. Structure-activity relationships for soluble 7-substituted 4-((3-bromophenyl)amino)pyrido(4,3-d)pyrimidines designed as inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor. Journal of Medicinal Chemistry 40(24): 3915-3925, 1997

Tyrosine kinase inhibitors. 13. Structure-activity relationships for soluble 7-substituted 4-[(3-bromophenyl)amino]pyrido[4,3-d]pyrimidines designed as inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor. Journal of Medicinal Chemistry 40(24): 3915-3925, 1997

Tyrosine kinase inhibitors. 10. Isomeric 4-[(3-bromophenyl)amino]pyrido[d]-pyrimidines are potent ATP binding site inhibitors of the tyrosine kinase function of the epidermal growth factor receptor. Journal of Medicinal Chemistry 39(9): 1823-1835, 1996

Tyrosine kinase inhibitors: 10. Isomeric 4-((3-bromophenyl)amino)pyrido(d)-pyrimidines are potent ATP binding site inhibitors of the tyrosine kinase function of the epidermal growth factor receptor. Journal of Medicinal Chemistry 39(9): 1823-1835, 1996

Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles The Design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor and the human epidermal growth factor receptor-2. Journal of Medicinal Chemistry 46(1): 49-63, January 2, 2003

Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2). Journal of Medicinal Chemistry 46(1): 49-63, 2002

Tyrosine kinase inhibitors. 7. 7-Amino-4-(phenylamino)- and 7-amino-4-((phenylmethyl)amino)pyrido(4,3-d)pyrimidines: A new class of inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor. Journal of Medicinal Chemistry 38(19): 3780-3788, 1995

Tyrosine kinase inhibitors. 7. 7-Amino-4-(phenylamino)- and 7-amino-4-[(phenylmethyl)amino]pyrido[4,3-d]pyrimidines: a new class of inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor. Journal of Medicinal Chemistry 38(19): 3780-3788, 1995

6-substituted-4- quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor and human epidermal growth factor receptor tyrosine kinases with enhanced antitumor activity. Journal of Medicinal Chemistry 44(17): 2719-2734, August 16, 2001

6-substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity. Journal of Medicinal Chemistry 44(17): 2719-2734, 2001

Sensitivities to various epidermal growth factor receptor-tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor-tyrosine kinase inhibitor?. Cancer Science 107(8): 1134-1140, 2016

Quinazoline and pyridopyrimidine acrylamides A new class of potent and selective irreversible inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor. Abstracts of Papers American Chemical Society 215(1-2): MEDI 118, 1998